Related Experiment Video

Updated: May 3, 2026

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.1K

MAP1S controls breast cancer cell TLR5 signaling pathway and promotes TLR5 signaling-based tumor suppression

Ming Shi1, Yuanfei Yao1, Fang Han1

  • 1School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.

Plos One
|January 28, 2014
PubMed

Insights

Toll-like receptor 5 (TLR5) signaling, activated by flagellin, inhibits breast cancer growth. Autophagy protein MAP1S is crucial, enhancing TLR5 pathway activity and mediating flagellin

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Targeting Toll-like receptor 5 (TLR5) signaling is a novel immunotherapy strategy for breast cancer.
  • The precise mechanisms by which TLR5 signaling inhibits cancer cell proliferation and tumor growth remain unclear.

Purpose of the Study:

  • To elucidate the mechanism of TLR5 signaling in inhibiting breast cancer cell proliferation and tumor growth.
  • To investigate the role of autophagy protein MAP1S in the flagellin/TLR5 signaling pathway in breast cancer.

Main Methods:

  • Treatment of breast cancer cells with flagellin, a TLR5 agonist.
  • Analysis of cell activation, autophagy induction, and NF-κB activity.
  • Assessment of MAP1S expression and its role in tumor suppression, growth, and migration.
  • Investigation of MAP1S-mediated regulation of the tumor inflammatory microenvironment and MyD88 degradation.

Main Results:

  • Flagellin treatment inhibited breast cancer cell activation and induced autophagy.
  • Autophagy protein MAP1S was identified as a regulator of the flagellin/TLR5 pathway, enhancing NF-κB activity and cytokine secretion.
  • MAP1S knockdown abrogated flagellin-induced suppression of tumor growth and migration.
  • MAP1S mediated feedback regulation of the tumor inflammatory microenvironment via MyD88 degradation in autophagy.

Conclusions:

  • MAP1S plays a critical role in the antitumor activity of flagellin/TLR5 signaling in breast cancer.
  • The findings reveal a novel mechanism of antitumor activity involving MAP1S-controlled TLR5 signaling and autophagy in breast cancer.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.1K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

12.4K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K